A decision-focused analysis combining process science, manufacturing risk, business feasibility, and execution lessons for CAR-T and lentiviral vector programs.
Every CAR-T startup leadership team eventually faces a version of the same conversation.
A scientific co-founder insists that Quality by Design principles must be embedded from the start — that understanding the process deeply before scaling is the only responsible path to a reliable medicine. A CFO or lead investor pushes back: the runway is finite, the clinical milestone is what drives the next round, and spending eighteen months on process characterization before the first patient is treated is a luxury the company cannot afford.
Both are right. Both are also incomplete.
The real problem in most failed or struggling programs is not that leadership chose QbD over speed, or speed over QbD. The real problem is that they never made a deliberate choice at all.
What QbD Actually Means in a CAR-T and LVV Context
Quality by Design is a systematic approach to pharmaceutical development in which quality is built into the product through the deliberate design and understanding of the process, rather than tested into the final product after the fact.
In the context of CAR-T manufacturing and lentiviral vector manufacturing, QbD means knowing which process parameters drive which quality attributes, understanding the ranges within which those parameters can vary without compromising product quality, and building that understanding into process design, analytical methods, and control strategies.
Phase I/II CMC Sweet Spot
Before IND
Defined process, release testing, patient safety, GMP readiness
Before Phase II
Process characterization, analytical validation path, scale-down model
Phase II/III
Design space validation, commercial process qualification, BLA readiness
What Speed Actually Means — And What It Costs
Speed-to-clinic in the advanced therapy space is not mere impatience. It is, in most cases, a legitimate strategic and financial imperative.
But speed has a cost structure that is often obscured at the time the decision is made. The costs of insufficient process understanding do not appear on the timeline at the moment of deferral. They appear later — at CDMO transfer, at scale-up, at analytical method validation, at the first failed batch, and at the first regulatory question.
The Deliberate Choice: A Framework for Phase I/II CMC Strategy
A useful way to structure the decision is to separate the CMC development workstream into three categories: what must be done before IND, what should be done before Phase II, and what can be deferred to Phase II/III.
Five Decision Points: Strategy vs. Drift
| Decision | Why It Matters |
|---|---|
| CQA hierarchy | Determines analytical and process development priorities |
| Process change philosophy | Defines when comparability or regulatory action is needed |
| Potency assay path | Prevents late analytical bottlenecks |
| CDMO transfer strategy | Turns vendor management into true CDMO management |
| Deferred CMC risk register | Makes speed tradeoffs visible and manageable |
Final Thoughts: The Choice Is Yours to Make
The tension between QbD and speed is real. The organizations that succeed in CGT industrialization are not those that always choose quality rigor over clinical speed, or always choose speed over rigor. They are the organizations that make the choice consciously, document the trade-offs explicitly, manage the accepted risks actively, and revisit the decision as circumstances evolve.
Most programs that fail do not fail because leadership chose wrong. They fail because leadership never chose.